Drug Trial Radar · NCT04658680
Can BCG Vaccination at First Health-facility Contact Reduce Early Infant Mortality?
Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
22,800
Planned (sponsor's estimate)
Start
Feb 25, 2021
Primary completion
Mar 2026
Study completion Jul 2026
Sponsor
- Lead sponsor
- Bandim Health ProjectAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Southern Denmark
- First posted
- Dec 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 day, up to 42 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Bacillus Calmette-Guérin (BCG) vaccination is recommended at birth to protect against tuberculosis (TB) in countries with high TB burden. BCG is supplied in multidose vials with limited durability after reconstitution. In Guinea-Bissau, this has led to a practice of only opening a BCG vial at specific days, and only if sufficient children are present. Therefore, BCG vaccination is frequently delayed. Accumulating evidence indicates that BCG has beneficial effects on survival beyond the specific protection against tuberculosis, so called non-specific effects (NSEs). The hypothesis of this study is that increasing the availability of BCG and vaccinating children at the first health-facility contact can reduce early infant non-accidental mortality by 25%. In a cluster-randomised crossover trial, 23 health facilities (HFs) in three rural regions in Guinea-Bissau will be randomised to either continue with current practice (typically BCG vaccination once a week if a sufficient number of children are present for vaccination); or to offer additional BCG vaccines to make BCG available every day and open a vial of BCG if there is just one eligible child present. All children born in the three regions and registered during the study period, will be eligible for inclusion into the trial 1 day after birth. If consent is given by the mother, the child will be followed until day 42 after birth, when other vaccines are scheduled to be given. The primary outcome will be non-accidental mortality, secondary outcomes are non-accidental hospital admissions, non-accidental neonatal mortality and cost-effectiveness of making BCG available at the first health-facility contact.
Conditions
- Infant Mortality
- BCG
Interventions
BCG vaccination at first health facility contactDrug
Intradermal injection at first health facility contact: 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine in the left deltoid region. The strain supplied by the national vaccination programme is provided through UNICEF. Different strains are used interchangeably. The additional BCG vaccines provided through this study will be procured by the Bandim Health Project. Vaccines will be from the WHO list of prequalified vaccines and the same strain will be used in intervention and control health centres.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Odds ratio of non-accidental early infant mortalityTime frame: From 1 day after birth to 42 days after birth
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bandim Health Project
Bissau, Guinea-Bissau
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.